Line 168: | Line 168: | ||
<p>In formula <b>(1)</b> RFP<sub>term</sub> and GFP<sub>term</sub> represent the number of fluorescence units from RFP and GFP respectively with the tested terminator in-between and RFP<sub>control</sub> and GFP<sub>control</sub> were taken from cultures containing the original plasmid BBa_I13514.</p> | <p>In formula <b>(1)</b> RFP<sub>term</sub> and GFP<sub>term</sub> represent the number of fluorescence units from RFP and GFP respectively with the tested terminator in-between and RFP<sub>control</sub> and GFP<sub>control</sub> were taken from cultures containing the original plasmid BBa_I13514.</p> | ||
− | <p>To test the terminator strength of our FRT-sequence, we created four different plasmids from BBa_I13415 as template:</p> | + | <p>To test the terminator strength of our FRT-sequence, we created four different plasmids from BBa_I13415 as template (see Figure 1):</p> |
<ul> | <ul> | ||
− | <li><b>FRT:</b> With the FRT-sequence in between GFP and RFP</li> | + | <li>•<b>FRT:</b> With the FRT-sequence in between GFP and RFP</li> |
− | <li><b>TRF:</b> With the inverted FRT-sequence in-between</li> | + | <li>•<b>TRF:</b> With the inverted FRT-sequence in-between</li> |
− | <li><b>RNDM</b> With a random sequence, as an additional control for calibration</li> | + | <li>•<b>RNDM</b> With a random sequence, as an additional control for calibration</li> |
− | <li><b>TERM</b> With the terminator <a href="http://parts.igem.org/Part:BBa_B1001" target="_blank">B1001</a> in-between, as positive control of termination | + | <li>•<b>TERM</b> With the terminator <a href="http://parts.igem.org/Part:BBa_B1001" target="_blank">B1001</a> in-between, as positive control of termination</li> |
</ul> | </ul> | ||
Revision as of 12:45, 31 October 2017
Overview
test
"lucky shot" D.I.v.e.r.t.
test
tRNA Priming
test
FRT Terminaton strength
For measurement of the FRT-Sequences' terminator strength we went with an adapted version of the protocol developed by Cassie Huang in Tom Knight's lab. From their experiments we took their plasmid for calibration, BBa_I13515. This plasmid contains a promoter, followed by two consecutive genes for GFP and RFP expression and finally a terminator. If a terminator is inserted in between GFP and RFP, the amount of expressed RFP is decreased relative to the amount of expressed GFP. This can be measured via fluorescence and the terminator strength can be calculated with the following formula (1) from Jason Kelly in Drew Endy's lab:
In formula (1) RFPterm and GFPterm represent the number of fluorescence units from RFP and GFP respectively with the tested terminator in-between and RFPcontrol and GFPcontrol were taken from cultures containing the original plasmid BBa_I13514.
To test the terminator strength of our FRT-sequence, we created four different plasmids from BBa_I13415 as template (see Figure 1):
- •FRT: With the FRT-sequence in between GFP and RFP
- •TRF: With the inverted FRT-sequence in-between
- •RNDM With a random sequence, as an additional control for calibration
- •TERM With the terminator B1001 in-between, as positive control of termination
self-splicing ribozyme
and the antibiotic resistance gene
Design
Selection of a self-splicing ribozyme:
For the proof of concept for D.I.V.E.R.T. an antibiotic resistance with an intron on the lagging strand is required. While in yeast there are plenty of well-described introns to choose from, in E. coli information is more rare. However, scientists already discovered group I and group II introns working in prokaryotes as well. For example, the Tetrahymena group I intron, or self-splicing ribozyme, is proven to exhibit splicing activity in vivo in E. coli without the expression of additional supporting proteins1. In contrast to other self-splicing ribozymes the Tetrahymena group I intron can easily be engineered to cut itself scarlessly. For the exact recognition of the splicing sites intron-exon pairing sequences are present in the wild type mRNA. The most important of these regions are called P1 and P10 (paired region 1 and 10)2. P1 determines the 5’ end of the self-splicing ribozyme and contains P1ex, which has a considerable influence on the splicing activity. P10 pairs with an exon sequence close to the 3’ end and is therefore signalling the 3’ end of the intron. Although P1 and P10 mark opposite ends of the intron, they are both located in the same region and it is worth noticing that P1 and P10 can overlap.
Selection of an antibiotic resistance:
For the Tetrahymena group I intron Guo et al. proposed in their publication3 that the 5’ adjacent exon sequence of the mRNA should consist of CUCUCU. Concerning this and the requirement of the intron being on the lagging strand we were looking for an antibiotic resistance with AGAGAG (reverse complementary to CUCUCU). We finally chose an ampicillin resistance, a β-lactamase5, which exhibits AGAGAA approximately in the middle of the gene4. By introducing a silent mutation (A357G) the desired 5’ adjacent exon sequence could be obtained. Furthermore, a BsaI recognition site (T718, C719, T720) was silently mutated to comply with our Golden Gate-cloning standard.
Design of the self-splicing ribozyme:
When the Tetrahymena group I intron is inserted into a foreign gene, the adjustment of P1 and P10 are crucial for the preservation of the self-splicing ability: The P10 region was exchanged for bases complementary to the 3’ adjacent exon sequence of the new β-lactamase gene. Because P1ex and P10 are overlapping, P1 was altered as well. Additionally, as Guo et al. suggests3, a non-complementary base pair was introduced in the P1ex sequence to promote splicing activity.
Experiments & Results
Proof of self-splicing:
To test the functionality of the engineered self-splicing Tetrahymena group I intron with the adjacent β-lactamase exon sequence, it was cloned into an expression vector and transformed into E. coli. The total mRNA was then purified and and a cDNA synthesis was performed using gene specific primer. For enhancing the amount of detectable DNA a PCR with was done afterwards. A gel electrophoresis was performed where both, spliced, and unspliced DNA was visible.
The 835 bp band was cut out and cleaned up. By performing a PCR the DNA was multiplied and subsequently sent for sequencing, which confirmed the self-splicing activity exactly as it was intended during the design.
Ampicillin resistance:
For the proof of concept a functional ampicillin resistance gene is required and, since the recombination is Flp/FRT mediated, a FRT sequence is introduced after the start and stop codon. Therefore, after Met 16 additional amino acids are expressed at the N-terminus of the ampicillin resistance gene. To test if the ampicillin resistance is still functional, this modified gene is cloned into an expression vector. After subsequent transformation into chemical competent E. Coli DH10b, cells are plated on LB low salt agar with 100 µg/mL ampicillin concentration. After an overnight incubation ampicillin resistant colonies were visible. For verification a colony was picked and its plasmid was purified and the instert sequenced.
[1]: Waring RB, Ray JA, Edwards SW, Scazzocchio C, Davies RW. The Tetrahymena rRNA intron self-splices in E. coli: in vivo evidence for the importance of key base-paired regions of RNA for RNA enzyme function. Cell. 1985 Feb;40(2):371-80.
[2]: Burke JM, Cech TR, Davies RW, Schweyen RJ, Shub DA, Szostak JW, Tabak HF. Structural conventions for group I introns. Nucleic Acids Res. 1987 Sep 25; 15(18): 7217–7221.
[3]: Guo F, Cech TR. In vivo selection of better self-splicing introns in Escherichia coli: the role of the P1 extension helix of the Tetrahymena intron. RNA. 2002 May;8(5):647-58.
[4]: Zhou W, Wang Y, Lin J. Functional cloning and characterization of antibiotic resistance genes from the chicken gut microbiome.Appl Environ Microbiol. 2012 Apr;78(8):3028-32. doi: 10.1128/AEM.06920-11. Epub 2012 Jan 27.
CRISPR assisted integration
test